Table 2.

Pathologic features

Patient	1		2	3	4	5	6	7	8	9	10		11	12
Glomeruli, n	17	20	32	18	10	21	14	19	10	17	24	9	22	31
Pattern of injury	MPGN	FPGN	MPGN	MPGN	MPGN	MPGN	MPGN	MesPGN	MesPGN	MPGN	MPGN	MPGN	MesPGN	DPGN
Global sclerosis, %	20	0	56	39	20	57	29	42	40	59	4	33	5	48
IFTA, %	50	0	30	70	30	30	30	30	10	60	20	30	20	70
IF microscopy (frozen)	C3 (3+) IgG (tr)	C3 (3+) IgM (tr)	C3 (3+) IgM (1+)	C3 (3+) IgM (1+)	C3 (3+)	C3 (3+)	C3 (2+)	C3 (3+)	C3 (3+)	C3 (3+) IgM (tr)	C3 (3+)	C3 (3+)	C3 (3+)	C3 (3+) IgM (<1+)
IF microscopy (paraffin, IgG/κ/λ)	n/a	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
C4d	n/a	MES (< 1+)	Neg	MES (1+)	MES (1+)	Neg	n/a	MES (<1+)	MES (1+)	MES (< 1+)	Neg	Neg	Neg	Neg
Ultrastructural localization of deposits	MES SEN SEP IN	MES SEN IN	MES SEN SEP	MES SEN IN	MES SEN SEP IN	DDD	MES SEN	MES SEP IN	MES SEN SEP IN	MES SEN SEP IN	MES SEN SEP	DDD	DDD	MES SEN SEP

MPGN, membranoproliferative glomerulonephritis; FPGN, focal proliferative glomerulonephritis; DPGN, diffuse proliferative glomerulonephritis; MesPGN, mesangial proliferative glomerulonephritis; IF, immunofluorescence; IFTA, interstitial fibrosis and tubular atrophy; MES, mesangial; SEN, subendothelial; SEP, subepithelial; IN, intramembranous; DDD, dense deposit disease.